Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples